Alfa Wassermann SpA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alfa Wassermann SpA
AstraZeneca is developing a COVID-19 vaccine as a “public health emergency not a commercial opportunity” but has to maintain its business growth plans at the same time.
Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study
Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials
The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.
- Other Names / Subsidiaries
- Bama-Geve S.L., ALFASIGMA